Back to Trials
NCT00178594Recruiting

Evaluation of Hemostasis in Bleeding and Thrombotic Disorders

The University of Texas Health Science Center, Houston

Start Date

10/1/2002

Completion Date

1/1/2028

Summary

The objective of this study will be to assess the coagulation system in-vitro in a variety of bleeding and clotting disorders using the ROTEG analyzer and the thrombin generation assay.

Detailed Description

This is an exploratory study involving blood coagulation assays in a select group of individuals receiving treatment for their congenital or acquired bleeding or clotting disorder at UTHealth Houston. The ROTEG is a newly developed coagulation analyzer which allows the continuous assessment of whole blood coagulation from the formation of the first fibrin fibers and activated platelets, to the formation of a three-dimensional whole blood clot until the eventual dissolution of the clot. This device will not be used as a diagnostic or procedure tool. No recommendations regarding interpretation of the results or implications for future treatment will be provided.

Eligibility Criteria

Age Range: No minimum to 98 years

Inclusion Criteria: patients with congenital or acquired bleeding or clotting disorders who have provided informed consent and/or assent Exclusion Criteria: poor venous access

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Blood Coagulation Disorders, InheritedThrombotic Disorder

Locations

The Univerisity of Texas Health Science Center at Houston

Houston, Texas 77030

United States

UT Physicians Women's Center-Texas Medical Center

Houston, Texas 77030

United States